What is survodutide?
Survodutide (development code BI 456906) is a synthetic peptide that activates two receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It was co-invented by Zealand Pharma and is being developed by Boehringer Ingelheim. It is being studied in the phase III SYNCHRONIZE programme in people with obesity or overweight, and in trials in metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease.
This listing was previously misspelled “Survotitude”. The correct name is survodutide.
Survodutide product specifications
- Compound: survodutide (BI 456906)
- Type: glucagon/GLP-1 receptor dual agonist peptide
- Vial size: please confirm with us when you inquire
How survodutide differs from related peptides
- Mazdutide also targets both the GLP-1 and glucagon receptors, but it is a different molecule from a different developer.
- Tirzepatide targets the GLP-1 and GIP receptors instead of glucagon.
- Retatrutide targets all three: GLP-1, GIP and glucagon receptors.
Regulatory status
Survodutide is an investigational drug. As of mid-2026 it had not been approved by the US FDA, the European Medicines Agency, the UK MHRA or Health Canada. US regulators have issued warning letters to companies selling GLP-1-type compounds labelled “for research use”. This product is sold for laboratory research use only.
Handling and research-use notice
Store and handle this material as stated on the label and certificate of analysis for your batch; see our guide to storing research peptides. This product is sold for laboratory research use only. It is not a medicine or supplement and is not for human or veterinary use.
Reviews
There are no reviews yet.